Trial · NCT03681184
Results by group60
Each measurement the trial posted, group by group, in the words and numbers it posted.
21 to 40 of 60
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change in Estimated Glomerular Filtration Rate (eGFR) From Baseline to Week 2 and Months 1, 2, 3, 4, 5 and 6 | Placebo/Lumasiran | Month 3 | -3 | Standard Deviation 6 | mL/min/1.73m^2 |
| Change in Estimated Glomerular Filtration Rate (eGFR) From Baseline to Week 2 and Months 1, 2, 3, 4, 5 and 6 | Lumasiran/Lumasiran | Month 3 | 0 | Standard Deviation 11 | mL/min/1.73m^2 |
| Change in Estimated Glomerular Filtration Rate (eGFR) From Baseline to Week 2 and Months 1, 2, 3, 4, 5 and 6 | Placebo/Lumasiran | Month 4 | -4 | Standard Deviation 8 | mL/min/1.73m^2 |
| Change in Estimated Glomerular Filtration Rate (eGFR) From Baseline to Week 2 and Months 1, 2, 3, 4, 5 and 6 | Lumasiran/Lumasiran | Month 4 | -4 | Standard Deviation 10 | mL/min/1.73m^2 |
| Change in Estimated Glomerular Filtration Rate (eGFR) From Baseline to Week 2 and Months 1, 2, 3, 4, 5 and 6 | Placebo/Lumasiran | Month 5 | -4 | Standard Deviation 7 | mL/min/1.73m^2 |
| Change in Estimated Glomerular Filtration Rate (eGFR) From Baseline to Week 2 and Months 1, 2, 3, 4, 5 and 6 | Lumasiran/Lumasiran | Month 5 | -6 | Standard Deviation 13 | mL/min/1.73m^2 |
| Change in Estimated Glomerular Filtration Rate (eGFR) From Baseline to Week 2 and Months 1, 2, 3, 4, 5 and 6 | Placebo/Lumasiran | Month 6 | 0 | Standard Deviation 6 | mL/min/1.73m^2 |
| Change in Estimated Glomerular Filtration Rate (eGFR) From Baseline to Week 2 and Months 1, 2, 3, 4, 5 and 6 | Lumasiran/Lumasiran | Month 6 | -3 | Standard Deviation 11 | mL/min/1.73m^2 |
| Absolute Change in 24-hour Urinary Oxalate Excretion Corrected for BSA From Baseline in the Extension Period | Placebo/Lumasiran | At Month 54 | -0.951 | Standard Deviation 0.6148 | mmol/24hr/1.73m^2 |
| Absolute Change in 24-hour Urinary Oxalate Excretion Corrected for BSA From Baseline in the Extension Period | Lumasiran/Lumasiran | At Month 54 | -1.086 | Standard Deviation 0.7678 | mmol/24hr/1.73m^2 |
| Absolute Change in 24-hour Urinary Oxalate Excretion Corrected for BSA From Baseline in the Extension Period | Lumasiran/Lumasiran | At Month 60 | -1.129 | Standard Deviation 0.7581 | mmol/24hr/1.73m^2 |
| Percentage Change in 24-hour Urinary Oxalate Excretion Corrected by BSA From Baseline in the Extension Period | Placebo/Lumasiran | At Month 54 | -55.57 | Standard Deviation 11.903 | percent change |
| Percentage Change in 24-hour Urinary Oxalate Excretion Corrected by BSA From Baseline in the Extension Period | Lumasiran/Lumasiran | At Month 54 | -53.87 | Standard Deviation 41.919 | percent change |
| Percentage Change in 24-hour Urinary Oxalate Excretion Corrected by BSA From Baseline in the Extension Period | Lumasiran/Lumasiran | At Month 60 | -53.98 | Standard Deviation 28.476 | percent change |
| Percentage of Time That 24-hour Urinary Oxalate is at or Below 1.5 × ULN During Lumasiran Treatment | Placebo/Lumasiran | 89.44 | Full Range 21.1 to 99.3 | percentage of time | |
| Percentage of Time That 24-hour Urinary Oxalate is at or Below 1.5 × ULN During Lumasiran Treatment | Lumasiran/Lumasiran | 89.23 | Full Range 1.7 to 98.6 | percentage of time | |
| Absolute Change in 24-hour Urinary Oxalate:Creatinine Ratio From Baseline in the Extension Period | Placebo/Lumasiran | At Month 54 | -0.145 | Standard Deviation 0.1242 | mmol/mmol |
| Absolute Change in 24-hour Urinary Oxalate:Creatinine Ratio From Baseline in the Extension Period | Lumasiran/Lumasiran | At Month 54 | -0.127 | Standard Deviation 0.1063 | mmol/mmol |
| Absolute Change in 24-hour Urinary Oxalate:Creatinine Ratio From Baseline in the Extension Period | Lumasiran/Lumasiran | At Month 60 | -0.138 | Standard Deviation 0.1162 | mmol/mmol |
| Change in Estimated Glomerular Filtration Rate (eGFR) From Baseline in the Extension Period | Placebo/Lumasiran | At Month 54 | -12.860 | Standard Deviation 9.5386 | mL/min/1.73m^2 |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03681184/results?page=2